Tarsus Pharmaceuticals announced in a press release that the company has completed its previously announced acquisition of Alkeus Pharmaceuticals. With the completion of the acquisition, Tarsus adds worldwide rights to gildeuretinol (ALK-001), an investigational molecular entity designed to reduce the accumulation of toxic dimers while preserving the normal visual cycle.

ALK-001 has received Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the US Food and Drug Administration (FDA) for Stargardt disease and is currently being evaluated in the global NORTHSTAR phase 3 trial, with topline data anticipated in 2029, according to the company. 

The acquisition of Alkeus, announced on August 6, 2026, closed following the satisfaction of the customary closing conditions set forth in the definitive merger agreement.